MedKoo Cat#: 319665 | Name: Asapiprant
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Asapiprant, also known as S-555739, is a the potent and selective DP1 receptor antagonist. Asapiprant exhibited high affinity and selectivity for the DP1 receptor. Significant suppression of antigen-induced nasal resistance, nasal secretion, and cell infiltration in nasal mucosa was observed with asapiprant treatment. In addition, treatment with asapiprant suppressed antigen-induced asthmatic responses, airway hyper-responsiveness, and cell infiltration and mucin production in lung. These results show that asapiprant is a potent and selective DP1 receptor antagonist, and exerts suppressive effects in the animal models of allergic diseases. Thus, asapiprant has potential as a novel therapy for allergic airway diseases.

Chemical Structure

Asapiprant
Asapiprant
CAS#932372-01-5

Theoretical Analysis

MedKoo Cat#: 319665

Name: Asapiprant

CAS#: 932372-01-5

Chemical Formula: C24H27N3O7S

Exact Mass: 501.1570

Molecular Weight: 501.55

Elemental Analysis: C, 57.47; H, 5.43; N, 8.38; O, 22.33; S, 6.39

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 350.00 Ready to ship
50mg USD 550.00 Ready to ship
100mg USD 950.00 Ready to ship
200mg USD 1,550.00 Ready to ship
500mg USD 2,650.00 Ready to ship
1g USD 3,950.00 Ready to ship
2g USD 6,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
S-555739; S 555739; S555739; Asapiprant
IUPAC/Chemical Name
2-(5-(4-((4-isopropoxyphenyl)sulfonyl)piperazin-1-yl)-2-(oxazol-2-yl)phenoxy)acetic acid
InChi Key
ZMZNWNTZRWXTJU-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H27N3O7S/c1-17(2)34-19-4-6-20(7-5-19)35(30,31)27-12-10-26(11-13-27)18-3-8-21(24-25-9-14-32-24)22(15-18)33-16-23(28)29/h3-9,14-15,17H,10-13,16H2,1-2H3,(H,28,29)
SMILES Code
O=C(O)COC1=CC(N2CCN(S(=O)(C3=CC=C(OC(C)C)C=C3)=O)CC2)=CC=C1C4=NC=CO4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Asapiprant is a DP1 receptor antagonist with a Ki of 0.44 nM.
In vitro activity:
TBD
In vivo activity:
In the animal models of allergic rhinitis, changes in nasal resistance, nasal secretion, and cell infiltration in nasal mucosa were assessed after antigen challenge with and without asapiprant. Similarly, in the animal models of asthma, the effect of antigen challenge with and without asapiprant on antigen-induced bronchoconstriction, airway hyper-responsiveness, mucin production, and cell infiltration in lung were assessed. Significant suppression of antigen-induced nasal resistance, nasal secretion, and cell infiltration in nasal mucosa was observed with asapiprant treatment. In addition, treatment with asapiprant suppressed antigen-induced asthmatic responses, airway hyper-responsiveness, and cell infiltration and mucin production in lung. These results show that asapiprant exerts suppressive effects in the animal models of allergic diseases. Reference: Eur J Pharmacol. 2015 Oct 15;765:15-23. https://www.sciencedirect.com/science/article/abs/pii/S0014299915301795?via%3Dihub
Solvent mg/mL mM
Solubility
DMSO 7.1 14.08
DMF 10.0 19.94
DMF:PBS (pH 7.2) (1:5) 0.2 0.32
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 501.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Takahashi G, Asanuma F, Suzuki N, Hattori M, Sakamoto S, Kugimiya A, Tomita Y, Kuwajima G, Abraham WM, Deguchi M, Arimura A, Shichijo M. Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol. 2015 Oct 15;765:15-23. doi: 10.1016/j.ejphar.2015.08.003. Epub 2015 Aug 12. PMID: 26277322.
In vitro protocol:
TBD
In vivo protocol:
1. Takahashi G, Asanuma F, Suzuki N, Hattori M, Sakamoto S, Kugimiya A, Tomita Y, Kuwajima G, Abraham WM, Deguchi M, Arimura A, Shichijo M. Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol. 2015 Oct 15;765:15-23. doi: 10.1016/j.ejphar.2015.08.003. Epub 2015 Aug 12. PMID: 26277322.
1: Bhalla M, Herring S, Lenhard A, Wheeler JR, Aswad F, Klumpp K, Rebo J, Wang Y, Wilhelmsen K, Fortney K, Bou Ghanem EN. The prostaglandin D2 antagonist asapiprant ameliorates clinical severity in young hosts infected with invasive Streptococcus pneumoniae. Infect Immun. 2024 May 7;92(5):e0052223. doi: 10.1128/iai.00522-23. Epub 2024 Apr 17. PMID: 38629842; PMCID: PMC11075459. 2: Wong LR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ, Thurman A, Pezzulo AA, Szachowicz PJ, Li P, Pan R, Klumpp K, Aswad F, Rebo J, Narumiya S, Murakami M, Zuniga S, Sola I, Enjuanes L, Meyerholz DK, Fortney K, McCray PB Jr, Perlman S. Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature. 2022 May;605(7908):146-151. doi: 10.1038/s41586-022-04630-3. Epub 2022 Mar 21. PMID: 35314834; PMCID: PMC9783543. 3: Goldwaser E, Laurent C, Lagarde N, Fabrega S, Nay L, Villoutreix BO, Jelsch C, Nicot AB, Loriot MA, Miteva MA. Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9. PLoS Comput Biol. 2022 Jan 26;18(1):e1009820. doi: 10.1371/journal.pcbi.1009820. PMID: 35081108; PMCID: PMC8820617. 4: Wong LR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ, Pezzulo AA, Szachowicz PJ, Klumpp K, Aswad F, Rebo J, Narumiya S, Murakami M, Meyerholz DK, Fortney K, McCray PB Jr, Perlman S. Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19. bioRxiv [Preprint]. 2021 Apr 21:2021.04.20.440676. doi: 10.1101/2021.04.20.440676. PMID: 33907749; PMCID: PMC8077574. 5: Santini G, Mores N, Malerba M, Mondino C, Macis G, Montuschi P. Investigational prostaglandin D2 receptor antagonists for airway inflammation. Expert Opin Investig Drugs. 2016 Jun;25(6):639-52. doi: 10.1080/13543784.2016.1175434. Epub 2016 Apr 25. PMID: 27094922. 6: Takahashi G, Asanuma F, Suzuki N, Hattori M, Sakamoto S, Kugimiya A, Tomita Y, Kuwajima G, Abraham WM, Deguchi M, Arimura A, Shichijo M. Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol. 2015 Oct 15;765:15-23. doi: 10.1016/j.ejphar.2015.08.003. Epub 2015 Aug 12. PMID: 26277322.